Erythromycin Ophthalmic Ointment, USP 0.5% (Sterile)

Manufacturer
Lake Erie Medical DBA Quality Care Products LLC
Effective date
2019-03-18
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
legacy-cache
Hydrated at
2026-08-02 00:29:20

Label at a glance#

ProductErythromycin
Active ingredientERYTHROMYCIN
Label structure10 sections

Indications and uses

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorr...

Dosage and administration

In the treatment of superficial ocular infections, erythromycin ophthalmic ointment approximately 1 cm in length should be applied directly to the infected eye(s) up to six times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial ophthalmia, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment shoul...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Erythromycin Ophthalmic Ointment, USP belongs to the macrolide group of antibiotics. The sterile ophthalmic ointment flows freely over the conjunctiva. Erythromycin base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin is an antibiotic produced from a strain of Streptomyces erythraeus. It is basic and readily forms a salt when combined with an acid. It has the following structural formula:

Erythromycin (structural formula)
Erythromycin (structural formula)

C37H67NO13

Mol. Wt. 733.94

Chemical Name: (3R•, 4S•, 5S•, 6R•, 7R•, 9R•, 11R•, 12R•, 13S•, 14R•)-4-[(2,6-Dideoxy-3-C-methyl-3-0-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7, 12, 13-trihydroxy-3, 5, 7, 9, 11, 13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2, 10-dione

Each Gram Contains: ACTIVE: Erythromycin, USP 5 mg (0.5%); INACTIVES: Mineral Oil, White Petrolatum.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Microbiology

MICROBIOLOGY SECTION

Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections: Streptococcus pyogenes (group A β-hemolytic), Alpha-hemolytic streptococci (viridans group); Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin); Streptococcus pneumoniae; Mycoplasma pneumoniae (Eaton Agent, PPLO); Haemophilus influenzae (not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved); Treponema pallidum; Corynebacterium diphtheriae; Neisseria gonorrhoeae; Chlamydia trachomatis.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.

For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis.

The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established.

For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

The use of antimicrobial agents may be associated with the overgrowth of non-susceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.

Information for Patients:

INFORMATION FOR PATIENTS SECTION

Avoid contaminating the tip of container with material from the eye, fingers or other source.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted. No evidence of impaired fertility or harm to the fetus that appeared related to erythromycin was reported in these studies.

Pregnancy:

PREGNANCY SECTION

Pregnancy Category B.

Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.

Nursing Mothers:

NURSING MOTHERS SECTION

Caution should be exercised when erythromycin is administered to a nursing woman.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequently reported adverse reactions are minor ocular irritations, redness and hypersensitivity reactions.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb, a division of Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

In the treatment of superficial ocular infections, erythromycin ophthalmic ointment approximately 1 cm in length should be applied directly to the infected eye(s) up to six times daily, depending on the severity of the infection.

For prophylaxis of neonatal gonococcal or chlamydial ophthalmia, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

HOW SUPPLIED

HOW SUPPLIED SECTION

Erythromycin Ophthalmic Ointment, USP 0.5% is available in the following sizes:

1/8 oz. (3.5 g) tamper-resistant tube - NDC 55700-478-35

DO NOT USE IF CAP AND NECKRING ARE NOT INTACT.

DO NOT USE IF BOTTOM RIDGE OF TUBE CAP IS EXPOSED.

Storage:

STORAGE AND HANDLING SECTION

Store between 15°-25°C (59°-77°F).

KEEP OUT OF REACH OF CHILDREN.

Revised: July 2016

Bausch + Lomb, a division of
Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA
©Bausch & Lomb Incorporated

9043404 (Folded)
9043504 (Flat)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

image descriptionimage description

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeData Matrix(01)00355700478353(21)0000000850(10)000504(17)#ERRORGTIN-14: 00355700478353
GTIN-12: 355700478353
UPC-A: 355700478353
EAN-13: 0355700478353
GTIN storage (14 digits): 00355700478353
New Doc 2017-02-06.jpg
Data codeQR Code55700047835\000504\#ERRORNew Doc 2017-02-06.jpg

FDA-Initiated Inactive NDC Indexing#

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
55700-478-35GM - Gram55700-4781e9cf999-7d50-4b2b-b438-24ab56ab08de12017-03-06
24208-910-19GM - Gram24208-9108e929d63-aea2-4e45-9ec1-4a255e8b769b12012-07-24
24208-910-55GM - Gram24208-9106a54f741-6969-4285-b0d6-73acf01c98dc12012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
55700-47855700-478-35
24208-910

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 3 matching rows.

Name, UNII, Kind table
NameUNIIKind
ERYTHROMYCIN63937KV33DACTIB
PETROLATUM4T6H12BN9UIACT
MINERAL OILT5L8T28FGPIACT

Source Document#

Source XML · Source PDF

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A064067-001ERYTHROMYCINERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A064067-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-2984e616aacf4f…
2026-08-18 06:07:402026-07A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICATRS1994-07-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-293f01610625f2…
2019-09-15 20:21 UTC2019-09A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-293a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064067-001ERYTHROMYCIN0.5%OINTMENT / OPHTHALMICAT1994-07-29f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A064067-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A064067-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A064067-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A064067-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A064067-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A064067-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A064067-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A064067-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A064067-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A064067-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A064067-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A064067-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A064067-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A064067-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A064067-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A064067-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A064067-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A064067-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A064067-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A064067-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A064067-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A064067-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A064067-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03A064067-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A064067-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A064067-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A064067-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09A064067-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07A064067-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A064067-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A064067-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A064067-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A064067-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A064067-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A064067-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A064067-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A064067-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A064067-001AT13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A064067-001AT13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A064067-001AT1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ErythromycinERYTHROMYCINBausch & Lomb Incorporated061ddd20-94a6-4e3c-ba84-1ebd8529eea62026-08-28Adverse reactionsExact identifier
ndc (product): 24208-910
db711a36-1684-4fdf-bf74-d5c634bc0111ea24e913-5ecc-4a0e-89ae-f8492f6a3de82025-01-09Adverse reactionsExact identifier
spl set id: ea24e913-5ecc-4a0e-89ae-f8492f6a3de8

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.